<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1059">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681430</url>
  </required_header>
  <id_info>
    <org_study_id>RES-Q-HR</org_study_id>
    <secondary_id>2020-004695-18</secondary_id>
    <nct_id>NCT04681430</nct_id>
  </id_info>
  <brief_title>Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals</brief_title>
  <acronym>RES-Q-HR</acronym>
  <official_title>Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Federal Ministry of Health, Germany (Bundesministerium für Gesundheit, BMG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 4-arm, multicenter, randomized, partly double- blind, controlled trial to&#xD;
      evaluate the safety and efficacy of convalescent serum (CP) or camostat mesylate with control&#xD;
      or placebo in adult patients diagnosed with SARS-CoV-2 and high risk for moderate/severe&#xD;
      COVID-19. The working hypothesis to be tested in the RES-Q-HR study is that the early use of&#xD;
      convalescent plasma (CP) or camostat mesylate (Foipan®) reduces the likelihood of disease&#xD;
      progression to modified WHO stages 4b-8 in SARS-CoV-2 positive adult patients at high risk of&#xD;
      moderate or severe COVID-19 progression. The primary endpoint of the study is the cumulative&#xD;
      number of individuals who progressed to or beyond category 4b on the modified WHO (World&#xD;
      Health Organization) COVID-19 ordinal scale within 28 days after randomization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated&#xD;
      COVID-19. No treatment is available for early disease stages and non-hospitalized patients to&#xD;
      date. This trial focusses on SARS-CoV-2 positive patients with pre-existing risk factors for&#xD;
      a moderate or severe COVID-19 disease course. This study is a 4-arm, multicenter, randomized,&#xD;
      partly double-blind, controlled trial to evaluate the safety and efficacy of convalescent&#xD;
      serum (CP) or camostat mesylate with control or placebo in adult patients diagnosed with&#xD;
      SARS-CoV-2 and high risk for moderate/severe COVID-19. Camostat mesylate acts as an inhibitor&#xD;
      of the host cell serine protease TMPRSS2 and prevents the virus from entering the cell.&#xD;
      Convalescent plasma (CP) represents another antiviral strategy in terms of passive&#xD;
      immunization. The working hypothesis to be tested in the RES-Q HR study is that the early use&#xD;
      of convalescent plasma (CP) or camostat mesylate (Foipan®) reduces the likelihood of disease&#xD;
      progression to modified WHO stages 4b-8 in SARS-CoV-2 positive adult patients at high risk of&#xD;
      moderate or severe COVID-19 progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a multicenter trial that will be conducted in approx. 10 - 15 centers in Germany.&#xD;
At each center, patients will be randomized into four groups: two treatment groups and two control groups. The randomization rate in this study is two to one (2:1) in favor to therapy, i.e.&#xD;
included patients have twice the chance to receive interventional therapy than placebo / SoC.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The camostat mesylate and its placebo group will be double blinded while the CP and its placebo will be open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>WHO ordinal Covid-19 scale up to day 28</measure>
    <time_frame>up to and including day 28</time_frame>
    <description>The primary endpoint of the study is the number of individuals whose clinical status is on the COVID-19 modified WHO ordinal scale ≥ 4b up to and including day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative number WHO categories 4b-8</measure>
    <time_frame>day 8, day 14, day 56 and day 90</time_frame>
    <description>Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 4b-8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number WHO categories 3-4a</measure>
    <time_frame>day 8, day 14, day 28, day 56 and day 90</time_frame>
    <description>Cumulative number of persons in the respective treatment arms versus SoC/placebo in WHO categories 3-4a</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Not hospitalized</measure>
    <time_frame>at day 90</time_frame>
    <description>Cumulative number of participants not hospitalized at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>at day 90</time_frame>
    <description>All-cause mortality at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinfection</measure>
    <time_frame>up to day 90</time_frame>
    <description>Number of patient with SARS-CoV-2 reinfection up to day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary sclerosing cholangitis (SSC)</measure>
    <time_frame>at day 90</time_frame>
    <description>Number of patient with secondary sclerosis cholangitis at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic pulmonary disease as sequelae from COVID-19</measure>
    <time_frame>at day 90</time_frame>
    <description>Number of patient with COVID-19 associated chronic pulmonary disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients with remdesivir treatment</measure>
    <time_frame>up to day 90</time_frame>
    <description>The proportion of patients with remdesivir therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 WHO status of patients at start of remdesivir treatment</measure>
    <time_frame>up to day 90</time_frame>
    <description>The clinical status on the WHO COVID-19 ordinal scale of at the start of remdesivir treatment WHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients with dexamethasone treatment</measure>
    <time_frame>up to day 90</time_frame>
    <description>The proportion of patients on dexamethasone therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 WHO status of patients at start of dexamethasone treatment</measure>
    <time_frame>up to day 90</time_frame>
    <description>The clinical status on the WHO COVID-19 ordinal scale of at the start of dexamethasone treatment&#xD;
WHO ordinal scale ranges from 0 to 8; whereas 0 = no COVID-19 infection and 8 = death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resolution of COVID-19 symptoms</measure>
    <time_frame>until day of resolution up to day 90</time_frame>
    <description>Time to resolution of COVID-19 related symptoms (e.g. fever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>negative SARS-CoV-2-PCR test</measure>
    <time_frame>until day of first negative test up to day 90</time_frame>
    <description>Time to first negative SARS-CoV-2-PCR (polymerase chain reaction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen therapy</measure>
    <time_frame>number of days with oxygen therapy up to day 90</time_frame>
    <description>Duration of oxygen therapy (in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 pneumonia</measure>
    <time_frame>up to day 90</time_frame>
    <description>Frequency of occurrence of COVID-19 pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants requiring mechanical ventilation</measure>
    <time_frame>up to day 90</time_frame>
    <description>Percentage of participants in each group with need for mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilation days per participant up to day 90</measure>
    <time_frame>up to day 90</time_frame>
    <description>Number of ventilation days per participant up to day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay and intensive care</measure>
    <time_frame>up to day 90</time_frame>
    <description>Duration of hospital stay (in days), duration in intensive care/intermediate care (IMC) (in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at day 28</time_frame>
    <description>All-cause mortality at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAEs</measure>
    <time_frame>up to day 90</time_frame>
    <description>Cumulative incidence of Serious Adverse Events (SAE) per group within 90 days follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3/4 AEs</measure>
    <time_frame>up to day 90</time_frame>
    <description>Cumulative incidence of grade 3/4 Adverse Events (AE) per group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 antibody IgA concentrations</measure>
    <time_frame>on day 8, day 14, day 90</time_frame>
    <description>SARS-CoV-2 antibody concentrations (IgA in g/l) in serum on day 8, day 14, day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 antibody IgG concentrations</measure>
    <time_frame>on day 8, day 14, day 90</time_frame>
    <description>SARS-CoV-2 antibody concentrations (IgG in g/l) in serum on day 8, day 14, day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 neutralizing antibody titers</measure>
    <time_frame>on day 8, day 14, day 90</time_frame>
    <description>SARS-CoV-2 neutralizing antibody titers in serum on day 8, day 14, day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma treatment screening failures</measure>
    <time_frame>up to day 8 (End of treatment)</time_frame>
    <description>Number of screening failures due to the lack of a suitable plasma preparation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1094</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>SARS-CoV-2 PCR Test Positive</condition>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>convalescent plasma (CP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 2 units of CP (neutralizing anti-SARS-CoV-2 antibody titer of at least 1:160) on day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care allowed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Camostat Mesilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets 600 mg per day in 3 doses over 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo camostat</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Tablets in 3 doses over 7 days (blinded)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>transfusion of convalescent plasma (CP) with neutralizing antibodies against anti-SARS-CoV-2 ((titer of at least 1:160)</description>
    <arm_group_label>convalescent plasma (CP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camostat Mesilate</intervention_name>
    <description>Tablets over 7 days, daily dose of 600 mg split into 3 doses</description>
    <arm_group_label>Camostat Mesilate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Camostat Mesilate</intervention_name>
    <description>Placebo Tablets over 7 days, split into 3 doses</description>
    <arm_group_label>Placebo camostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care (SoC)</intervention_name>
    <description>Control Arm for convalescent plasma (CP)</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals (female, male, diverse) ≥ 18 years with SARS-CoV-2 infection, confirmed by&#xD;
             PCR before study enrollment&#xD;
&#xD;
          2. SARS-CoV-2 positive PCR ≤ 3 days old (date of NP swab)&#xD;
&#xD;
          3. Presence of ≥ 1 SARS-CoV-2 typical symptom (fever, cough, shortness of breath, sore&#xD;
             throat, headache, fatigue, smell/and or taste disorder, diarrhea, abdominal symptoms,&#xD;
             exanthema) and symptom duration &lt;= 3 days.&#xD;
&#xD;
          4. Ability to provide written informed consent&#xD;
&#xD;
          5. Presence of at least one of the following criteria:&#xD;
&#xD;
               -  Patients &gt; 75 years&#xD;
&#xD;
               -  Patients &gt; 65 years with at least one other risk factor (BMI &gt;35 kg/m2, coronary&#xD;
                  artery disease, chronic kidney disease (CKD) with glomerular filtration rate&#xD;
                  (GFR) &lt;60 ml/min but &gt;= 30 ml/min, diabetes mellitus, active tumor disease)&#xD;
&#xD;
               -  Patients with a BMI &gt;35 kg/m2 with at least one other risk factor (CAD, CKD with&#xD;
                  GFR &lt;60 ml/min but &gt;= 30 ml/min, diabetes mellitus, active tumor disease)&#xD;
&#xD;
               -  Patients with a BMI &gt;40 kg/m2&#xD;
&#xD;
               -  Patients with chronic obstructive pulmonary disease (COPD) and/or pulmonary&#xD;
                  fibrosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years&#xD;
&#xD;
          2. Unable to give informed consent&#xD;
&#xD;
          3. Pregnant women or breast-feeding mothers&#xD;
&#xD;
          4. Previous transfusion reaction or other contraindication to a plasma transfusion&#xD;
&#xD;
          5. Known hypersensitivity to camostat mesylate and/or severe pancreatitis&#xD;
&#xD;
          6. Volume stress due to CP administration would be intolerable&#xD;
&#xD;
          7. Known IgA deficiency&#xD;
&#xD;
          8. Life expectancy &lt; 6 months&#xD;
&#xD;
          9. Duration SARS-CoV-2 typical symptoms &gt; 3 days&#xD;
&#xD;
         10. SARS-CoV-2 PCR detection older than 3 days&#xD;
&#xD;
         11. SARS-CoV-2 associated clinical condition &gt;= WHO stage 3 (patients hospitalized for&#xD;
             other reasons than COVID-19 may be included if they fulfill all inclusion and none of&#xD;
             the exclusion criteria).&#xD;
&#xD;
         12. Previously or currently hospitalized due to SARS-CoV-2&#xD;
&#xD;
         13. Previous antiviral therapy for SARS-CoV-2&#xD;
&#xD;
         14. alanine aminotransferase (ALT) or aspartate transferase (AST) &gt; 5 times upper limit of&#xD;
             normal (ULN) at screening&#xD;
&#xD;
         15. Liver cirrhosis &gt; Child A (patients with Child B/C cirrhosis are excluded from the&#xD;
             trial)&#xD;
&#xD;
         16. Chronic kidney disease with GFR &lt; 30 ml/min&#xD;
&#xD;
         17. Concurrent or planned anticancer treatment during trial period&#xD;
&#xD;
         18. Accommodation in an institution due to legal orders (§40(4) AMG).&#xD;
&#xD;
         19. Any psycho-social condition hampering compliance with the study protocol.&#xD;
&#xD;
         20. Evidence of current drug or alcohol abuse.&#xD;
&#xD;
         21. Use of other investigational treatment within 5 half-lives of enrollment is prohibited&#xD;
&#xD;
         22. Previous use of convalescent plasma for COVID-19&#xD;
&#xD;
         23. Concomitant proven influenza A infection&#xD;
&#xD;
         24. Patients with organ or bone marrow transplant in the three months prior to Screening&#xD;
             Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Verena Keitel-Anselmino, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Gastroenterologie, Hepatologie und Infektiologie Universitätsklinikum Düsseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Verena Keitel-Anselmino, Prof.Dr.med.</last_name>
    <phone>+49211-81-16330</phone>
    <email>keitelan@uni-duesseldorf.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abteilung Infektiologie Klinik für Innere Medizin II Department Innere Medizin Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Winfried Kern, Prof. Dr. med.</last_name>
      <phone>+49761 270 18190</phone>
      <email>winfried.kern@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Innere Medizin II Klinikum rechts der Isar Technische Universität München</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Spinner, PD Dr. med.</last_name>
      <phone>+49 89 41 40 24 55</phone>
      <email>christoph.spinner@mri.tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Medizinische Klinik 2: Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie/HIV</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timo Wolf, PD Dr. med.</last_name>
      <phone>+49 69 6301 5452</phone>
      <email>Timo.Wolf@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf Klinik für Hepatologie und Infektiologie</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Verena Keitel, Univ. Prof. Dr. med.</last_name>
      <phone>+492118118268</phone>
      <email>RESQ-Studie@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Covid-19</keyword>
  <keyword>camostat mesilate</keyword>
  <keyword>reconvalescent plasma</keyword>
  <keyword>TMPRSS2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabexate</mesh_term>
    <mesh_term>Camostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

